In patients with HIV infection, it was demonstrated that the suPAR level is slightly elevated and increases with the disease stage (WHO criteria). The first study of suPAR in HIV showed that suPAR was at least as strong a prognostic marker of the natural progression of HIV as CD4 and viral load1. Antiretroviral therapy (ART) causes a decrease in suPAR of about 17%2. However, after 5 years of treatment, the patients’ suPAR level is still higher than in healthy controls2. Side effects of treatment are associated with higher suPAR levels3. In addition to the correlation with virological and immunological effects of the infection, the suPAR level correlates with age, metabolic syndrome, smoking, and low muscle mass4. In HIV patients with ARTinduced viral suppression, suPAR is a superior and independent predictor of non-AIDS events comorbidities (e.g. cardiovascular and renal diseases).